We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+5.06%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$11.8B
AUM Growth
+$261M
Cap. Flow
+$368M
Cap. Flow %
3.12%
Top 10 Hldgs %
80.71%
Holding
127
New
5
Increased
21
Reduced
20
Closed
13

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$268M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$210M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$46.6M
4
HRTX icon
Heron Therapeutics
HRTX
+$44.6M
5
ACGN
Aceragen Inc
ACGN
+$41M

Top Sells

Rank Stock Value
1
ABLX
Ablynx NV
ABLX
+$98.3M
2
RXDX
Ignyta, Inc.
RXDX
+$37M
3
IMGN
Immunogen Inc
IMGN
+$16.4M
4
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$10.8M
5
ANAB icon
AnaptysBio
ANAB
+$10.2M

Sector Composition

Rank Sector Weight
1 Healthcare 93.85%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INCY icon
1
Incyte
INCY
$25.7B
$2.85B 24.18%
34,230,751
+228
+0% +$20.6K
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
$2.59B 21.99%
49,575,409
+3,849,853
+8% +$210M
ONC
3
BeOne Medicines Ltd
ONC
$33.9B
$979M 8.3%
5,829,429
+1,980,198
+51% +$268M
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
$954M 8.08%
8,555,894
+2,030
+0% +$243K
BMRN icon
5
BioMarin Pharmaceuticals
BMRN
$11.9B
$615M 5.21%
7,583,084
– –
ACAD icon
6
Acadia Pharmaceuticals
ACAD
$4.5B
$612M 5.19%
27,228,338
– –
GHDX
7
DELISTED
Genomic Health, Inc.
GHDX
$431M 3.66%
13,789,936
+8,834
+0.1% +$293K
ASND icon
8
Ascendis Pharma A/S
ASND
$16.6B
$186M 1.57%
2,837,352
+218,534
+8% +$12.3M
NGNE icon
9
Neurogene
NGNE
$656M
$154M 1.3%
546,708
– –
AVXS
10
DELISTED
AveXis, Inc. Common Stock
AVXS
$144M 1.22%
1,167,157
+392,157
+51% +$46.6M
HRTX icon
11
Heron Therapeutics
HRTX
$92.5M
$139M 1.18%
5,025,298
+1,964,657
+64% +$44.6M
DBVT
12
DBV Technologies
DBVT
$795M
$127M 1.08%
550,956
– –
ABLX
13
DELISTED
Ablynx NV
ABLX
$119M 1.01%
2,176,802
-1,984,316
-48% -$98.3M
SAGE
14
DELISTED
Sage Therapeutics
SAGE
$104M 0.88%
646,828
+30,314
+5% +$5.15M
ARRY
15
DELISTED
Array Biopharma Inc
ARRY
$92.3M 0.78%
5,656,196
– –
ONCE
16
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$92.2M 0.78%
1,384,130
– –
NBIX icon
17
Neurocrine Biosciences
NBIX
$18.3B
$78.3M 0.66%
944,624
-60,000
-6% -$5.07M
MRTX
18
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$78.3M 0.66%
2,549,461
– –
ARGX icon
19
argenx
ARGX
$55.1B
$77.4M 0.66%
961,754
– –
MDGL icon
20
Madrigal Pharmaceuticals
MDGL
$12.5B
$71.9M 0.61%
615,684
– –
ACGN
21
DELISTED
Aceragen Inc
ACGN
$71.1M 0.6%
284,413
+149,603
+111% +$41M
AMRN
22
Amarin Corp
AMRN
$302M
$68.2M 0.58%
1,133,475
– –
BCRX icon
23
BioCryst Pharmaceuticals
BCRX
$2.45B
$66.8M 0.57%
14,012,172
+15,000
+0.1% +$77.1K
PHXM
24
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$64.9M 0.55%
309,007
– –
CERS icon
25
Cerus
CERS
$575M
$58.9M 0.5%
10,749,937
+1,004,728
+10% +$4.57M
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2018 Portfolio in Review

As of Q1 2018, Baker Bros. Advisors held 127 positions worth $11.8B, up 2.3% from $11.5B the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Baker Bros. Advisors deployed $368M of net new capital in Q1 2018, opening 5 new positions and adding to 21 existing holdings. Its largest new stake was VYNE Therapeutics: 194 shares worth $26.3M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Ablynx NV, an estimated $98.3M trimmed.

  • Baker Bros. Advisors's largest Q1 2018 buy was VYNE Therapeutics: 194 shares worth $26.3M.
  • Baker Bros. Advisors added most to BeOne Medicines Ltd in Q1 2018, an estimated $268M increase.
  • Baker Bros. Advisors's biggest Q1 2018 reduction was Ablynx NV, cutting an estimated $98.3M.
  • Baker Bros. Advisors fully exited Ignyta, Inc. in Q1 2018, selling an estimated $37M.
  • Baker Bros. Advisors's ten largest holdings make up 81% of its $11.8B portfolio in Q1 2018.
  • Baker Bros. Advisors opened 5 new positions and closed 13 in Q1 2018.
  • Baker Bros. Advisors's portfolio value rose 2.3% quarter-over-quarter to $11.8B.

Based on Baker Bros. Advisors's 13F filing for Q1 2018, filed 15 May 2018.